Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Return on Sales (2018 - 2025)

Historic Return on Sales for Catalyst Pharmaceuticals (CPRX) over the last 12 years, with Q3 2025 value amounting to 0.36%.

  • Catalyst Pharmaceuticals' Return on Sales rose 100.0% to 0.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.38%, marking a year-over-year increase of 900.0%. This contributed to the annual value of 0.33% for FY2024, which is 1800.0% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Return on Sales is 0.36%, which was up 100.0% from 0.36% recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Return on Sales peaked at 0.42% during Q4 2022, and registered a low of 0.3% during Q3 2023.
  • For the 5-year period, Catalyst Pharmaceuticals' Return on Sales averaged around 0.3%, with its median value being 0.34% (2024).
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Return on Sales tumbled by -11900bps in 2021, and later surged by 6400bps in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Return on Sales stood at 0.24% in 2021, then soared by 73bps to 0.42% in 2022, then tumbled by -50bps to 0.21% in 2023, then skyrocketed by 88bps to 0.39% in 2024, then dropped by -9bps to 0.36% in 2025.
  • Its Return on Sales stands at 0.36% for Q3 2025, versus 0.36% for Q2 2025 and 0.4% for Q1 2025.